Patents by Inventor Cheol Hee LIM

Cheol Hee LIM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11713308
    Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: August 1, 2023
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Eui Chul Lee, Sol Park, Hyok Jun Cho, Cheol Hee Lim, So Young Kim, Hyun Ho Choi, Da Na Jeong, Na Yeon Yang, Na Ry Ha
  • Publication number: 20230044255
    Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Application
    Filed: July 6, 2021
    Publication date: February 9, 2023
    Inventors: Tae Dong HAN, Hee Jae TAK, Eun Kyung KIM, Eui Chul LEE, Sol PARK, Hyok Jun CHO, Cheol Hee LIM, So Young KIM, Hyun Ho CHOI, Da Na JEONG, Na Yeon YANG, Na Ry HA
  • Publication number: 20220380324
    Abstract: The present technology provides triazolones, tetrazolones, and imidazolones, or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolones, tetrazolones, and imidazolones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Application
    Filed: April 21, 2022
    Publication date: December 1, 2022
    Inventors: Hee Jae TAK, Eun Kyung KIM, Hyok Jun CHO, Cheol Hee LIM
  • Patent number: 11332436
    Abstract: The present technology provides a process for selectively preparing an (E)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound by refluxing an (E/Z)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound in an organic solvent, followed by crystallization by cooling.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: May 17, 2022
    Assignee: Yuhan Corporation
    Inventors: Woo Seob Shin, Cheol Hee Lim
  • Patent number: 11168073
    Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: November 9, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Eui Chul Lee, Sol Park, Hyok Jun Cho, Cheol Hee Lim, So Young Kim, Hyun Ho Choi, Da Na Jeong, Na Yeon Yang, Na Ry Ha
  • Publication number: 20210230103
    Abstract: The present technology provides a process for selectively preparing an (E)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound by refluxing an (E/Z)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound in an organic solvent, followed by crystallization by cooling.
    Type: Application
    Filed: July 1, 2019
    Publication date: July 29, 2021
    Inventors: Woo Seob SHIN, Cheol Hee LIM
  • Publication number: 20200223827
    Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Application
    Filed: December 12, 2019
    Publication date: July 16, 2020
    Inventors: Tae Dong HAN, Hee Jae TAK, Eun Kyung KIM, Eui Chul LEE, Sol PARK, Hyok Jun CHO, Cheol Hee LIM, So Young KIM, Hyun Ho CHOI, Da Na JEONG, Na Yeon YANG, Na Ry HA